---
document_datetime: 2025-12-02 06:03:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-mylan.html
document_name: sugammadex-mylan.html
version: success
processing_time: 0.1264172
conversion_datetime: 2025-12-28 02:14:20.333772
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sugammadex Mylan

[RSS](/en/individual-human-medicine.xml/67492)

##### Authorised

This medicine is authorised for use in the European Union

sugammadex Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sugammadex Mylan](#news-on)
- [More information on Sugammadex Mylan](#more-information-on-sugammadex-mylan-1620)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sugammadex Mylan is a medicine used to reverse the effect of the muscle relaxants rocuronium and vecuronium. Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe. Muscle relaxants make it easier for the surgeon to do the operation. Sugammadex Mylan is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.

Sugammadex Mylan can be used in adults who have received rocuronium and vecuronium, and in children from birth who have received rocuronium.

Sugammadex Mylan contains the active substance sugammadex and is a 'generic medicine'. This means that Sugammadex Mylan contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Sugammadex Mylan is Bridion. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Sugammadex Mylan used?

Sugammadex Mylan can only be obtained with a prescription. It is given by or under the supervision of an anaesthetist (a doctor specialised in anaesthesia). Sugammadex Mylan is given into a vein as a single 'bolus' injection (given all at once).

For more information about using Sugammadex Mylan, see the package leaflet or contact your doctor or pharmacist.

## How does Sugammadex Mylan work?

The active substance in Sugammadex Mylan, sugammadex, attaches to the muscle relaxants rocuronium and vecuronium forming , stopping them from having an effect. As a result, the muscles contract and begin to work normally again, including the muscles that help the patient to breathe.

## How has Sugammadex Mylan been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Bridion, and do not need to be repeated for Sugammadex Mylan.

As for every medicine, the company provided studies on the quality of Sugammadex Mylan. There was no need for 'bioequivalence' studies to investigate whether Sugammadex Mylan is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Sugammadex Mylan is given by injection into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Sugammadex Mylan?

Because Sugammadex Mylan is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Sugammadex Mylan authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sugammadex Mylan has been shown to be comparable to Bridion. Therefore, the Agency's view was that, as for Bridion, the benefits of Sugammadex Mylan outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sugammadex Mylan?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sugammadex Mylan have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sugammadex Mylan are continuously monitored. Suspected side effects reported with Sugammadex Mylan are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sugammadex Mylan

Sugammadex Mylan received a marketing authorisation valid throughout the EU on 15 November 2021.

Sugammadex Mylan : EPAR - Medicine overview

Reference Number: EMADOC-1829012207-24008

English (EN) (133.51 KB - PDF)

**First published:** 22/11/2021

**Last updated:** 16/07/2025

[View](/en/documents/overview/sugammadex-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-98)

български (BG) (155.95 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/bg/documents/overview/sugammadex-mylan-epar-medicine-overview_bg.pdf)

español (ES) (133.32 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/es/documents/overview/sugammadex-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (153.78 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/cs/documents/overview/sugammadex-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (133.27 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/da/documents/overview/sugammadex-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (135.88 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/de/documents/overview/sugammadex-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (130.92 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/et/documents/overview/sugammadex-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (157.44 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/el/documents/overview/sugammadex-mylan-epar-medicine-overview_el.pdf)

français (FR) (133.64 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/fr/documents/overview/sugammadex-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (153.12 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/hr/documents/overview/sugammadex-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (132.35 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/it/documents/overview/sugammadex-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (150.59 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/lv/documents/overview/sugammadex-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (153.26 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/lt/documents/overview/sugammadex-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (153.93 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/hu/documents/overview/sugammadex-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (156.17 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/mt/documents/overview/sugammadex-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (134.18 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/nl/documents/overview/sugammadex-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (159.5 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/pl/documents/overview/sugammadex-mylan-epar-medicine-overview_pl.pdf)

português (PT) (133.31 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/pt/documents/overview/sugammadex-mylan-epar-medicine-overview_pt.pdf)

română (RO) (152.65 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/ro/documents/overview/sugammadex-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (154.43 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/sk/documents/overview/sugammadex-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (151.33 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/sl/documents/overview/sugammadex-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (130.95 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/fi/documents/overview/sugammadex-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (131.17 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

16/07/2025

[View](/sv/documents/overview/sugammadex-mylan-epar-medicine-overview_sv.pdf)

Sugammadex Mylan : EPAR - Risk-management-plan summary

English (EN) (82.72 KB - PDF)

**First published:** 22/11/2021

[View](/en/documents/rmp-summary/sugammadex-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Sugammadex Mylan : EPAR - Product information

English (EN) (458.53 KB - PDF)

**First published:** 22/11/2021

**Last updated:** 11/06/2025

[View](/en/documents/product-information/sugammadex-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-653)

български (BG) (513.64 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/bg/documents/product-information/sugammadex-mylan-epar-product-information_bg.pdf)

español (ES) (405.49 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/es/documents/product-information/sugammadex-mylan-epar-product-information_es.pdf)

čeština (CS) (448.13 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/cs/documents/product-information/sugammadex-mylan-epar-product-information_cs.pdf)

dansk (DA) (521.89 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/da/documents/product-information/sugammadex-mylan-epar-product-information_da.pdf)

Deutsch (DE) (531.95 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/de/documents/product-information/sugammadex-mylan-epar-product-information_de.pdf)

eesti keel (ET) (235.22 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/et/documents/product-information/sugammadex-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (445.97 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/el/documents/product-information/sugammadex-mylan-epar-product-information_el.pdf)

français (FR) (509.12 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/fr/documents/product-information/sugammadex-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (547.06 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/hr/documents/product-information/sugammadex-mylan-epar-product-information_hr.pdf)

íslenska (IS) (512.62 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/is/documents/product-information/sugammadex-mylan-epar-product-information_is.pdf)

italiano (IT) (523.12 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/it/documents/product-information/sugammadex-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (445.97 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/lv/documents/product-information/sugammadex-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (291.26 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/lt/documents/product-information/sugammadex-mylan-epar-product-information_lt.pdf)

magyar (HU) (583.01 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/hu/documents/product-information/sugammadex-mylan-epar-product-information_hu.pdf)

Malti (MT) (508.74 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/mt/documents/product-information/sugammadex-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (389.88 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/nl/documents/product-information/sugammadex-mylan-epar-product-information_nl.pdf)

norsk (NO) (403.35 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/no/documents/product-information/sugammadex-mylan-epar-product-information_no.pdf)

polski (PL) (524.38 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/pl/documents/product-information/sugammadex-mylan-epar-product-information_pl.pdf)

português (PT) (530.9 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/pt/documents/product-information/sugammadex-mylan-epar-product-information_pt.pdf)

română (RO) (437.48 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/ro/documents/product-information/sugammadex-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (543.48 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/sk/documents/product-information/sugammadex-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (341.73 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/sl/documents/product-information/sugammadex-mylan-epar-product-information_sl.pdf)

Suomi (FI) (514.57 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/fi/documents/product-information/sugammadex-mylan-epar-product-information_fi.pdf)

svenska (SV) (324.56 KB - PDF)

**First published:**

22/11/2021

**Last updated:**

11/06/2025

[View](/sv/documents/product-information/sugammadex-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000267163 06/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sugammadex Mylan : EPAR - All authorised presentations

English (EN) (15.89 KB - PDF)

**First published:** 22/11/2021

[View](/en/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-796)

български (BG) (32.11 KB - PDF)

**First published:**

22/11/2021

[View](/bg/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.4 KB - PDF)

**First published:**

22/11/2021

[View](/es/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.56 KB - PDF)

**First published:**

22/11/2021

[View](/cs/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (24.27 KB - PDF)

**First published:**

22/11/2021

[View](/da/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.59 KB - PDF)

**First published:**

22/11/2021

[View](/de/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (8.27 KB - PDF)

**First published:**

22/11/2021

[View](/et/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (21.76 KB - PDF)

**First published:**

22/11/2021

[View](/el/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (10.95 KB - PDF)

**First published:**

22/11/2021

[View](/fr/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (17.87 KB - PDF)

**First published:**

22/11/2021

[View](/hr/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.43 KB - PDF)

**First published:**

22/11/2021

[View](/is/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (15.91 KB - PDF)

**First published:**

22/11/2021

[View](/it/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (23.52 KB - PDF)

**First published:**

22/11/2021

[View](/lv/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (50.91 KB - PDF)

**First published:**

22/11/2021

[View](/lt/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.3 KB - PDF)

**First published:**

22/11/2021

[View](/hu/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.61 KB - PDF)

**First published:**

22/11/2021

[View](/mt/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (10.74 KB - PDF)

**First published:**

22/11/2021

[View](/nl/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.19 KB - PDF)

**First published:**

22/11/2021

[View](/no/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (26.87 KB - PDF)

**First published:**

22/11/2021

[View](/pl/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (11.41 KB - PDF)

**First published:**

22/11/2021

[View](/pt/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (26.08 KB - PDF)

**First published:**

22/11/2021

[View](/ro/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (22.99 KB - PDF)

**First published:**

22/11/2021

[View](/sk/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (29.15 KB - PDF)

**First published:**

22/11/2021

[View](/sl/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.53 KB - PDF)

**First published:**

22/11/2021

[View](/fi/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.46 KB - PDF)

**First published:**

22/11/2021

[View](/sv/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sugammadex Mylan Active substance sugammadex sodium International non-proprietary name (INN) or common name sugammadex Therapeutic area (MeSH) Neuromuscular Blockade Anatomical therapeutic chemical (ATC) code V03AB35

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults.

For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

## Authorisation details

EMA product number EMEA/H/C/005403

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park,

Opinion adopted 16/09/2021 Marketing authorisation issued 15/11/2021 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sugammadex Mylan: EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (165.86 KB - PDF)

**First published:** 12/03/2025

**Last updated:** 11/06/2025

[View](/en/documents/procedural-steps-after/sugammadex-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sugammadex Mylan: EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (162.12 KB - PDF)

**First published:** 03/10/2022

**Last updated:** 12/03/2025

[View](/en/documents/procedural-steps-after/sugammadex-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sugammadex Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/555625/2021

English (EN) (424.34 KB - PDF)

**First published:** 22/11/2021

[View](/en/documents/assessment-report/sugammadex-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sugammadex Mylan

Adopted

Reference Number: EMA/CHMP/493758/2021

English (EN) (148.1 KB - PDF)

**First published:** 17/09/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-mylan_en.pdf)

#### News on Sugammadex Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021) 17/09/2021

#### More information on Sugammadex Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 16/07/2025

## Share this page

[Back to top](#main-content)